P r o g r a m C h a i r sC h a i r

Morton Coleman, MDCenter for Lymphoma and Myeloma

Weill Cornell Medical College The New York Presbyterian Hospital

New York, New York

C o - C h a i r, L y m p h o m a S e s s i o nJohn P. Leonard, MD

Center for Lymphoma and Myeloma Weill Cornell Medical College

The New York Presbyterian Hospital New York, New York

C o - C h a i r, My e l o m a S e s s i o nRuben Niesvizky, MD

Center for Lymphoma and Myeloma Weill Cornell Medical College

The New York Presbyterian Hospital New York, New York

C o - C h a i r, L e u k e m i a S e s s i o nRichard R. Furman, MD

Center for Lymphoma and Myeloma Weill Cornell Medical College

The New York Presbyterian Hospital New York, New York

W W W . I M E D E X . C O M

October 22-24, 2009 I New York, New York The Waldorf=Astoria

2nd Announcement

October 16-18, 2008 • New York, New York • The Waldorf=Astoria

A comprehensive forum presenting the most recent developments in lymphocytic and plasma cell neoplasms

D ear C o l l e a g u e ,It is our pleasure to invite you to join us at Lymphoma & Myeloma 2009: An International Congress on Hematologic Malignancies. This fall’s Congress, October 22-24, 2009 at The Waldorf=Astoria in New York, New York, promises to be our most exciting and interactive meeting yet!

Since its inception in 2000, this Congress has grown to nearly 800 attendees and has become the premier forum for discussion on the latest advances in lymphoma and myeloma. Using a dynamic approach, featuring clinical controversies, debates, and examinations of current treatment regimens, attendees will receive a thorough understanding of the evolution of thought and therapy of lymphoma and myeloma, as well as any significant developments which may lead to improved results.

Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress will provide for a stimulating and interactive forum for attendees from all relevant medical specialties.

Allowing attendees the benefit of visiting New York City during one of the most beautiful times of year, this Congress will be the perfect chance for you to get away and enjoy a weekend of learning in the capital city of the world.

We cordially welcome you to our fair city and promise to reward you with an exciting, informative Congress!

Sincerely,

Morton Coleman, MD, Chair

John P. Leonard, MD, Co-Chair, Lymphoma Session

Ruben Niesvizky, MD, Co-Chair, Myeloma Session

Richard R. Furman, MD, Co-Chair, Leukemia Session

October 22-24, 2009 I New York, New York I The Waldorf=Astoria

C o n g re s s O rg a n i z e r

Dark Blue C100, M55, Y0, K55

Light Blue C29, M12, Y0, K0

Orange C0, M66, Y100, K0

4325 Alexander Drive Alpharetta, Georgia 30022-3740, USA Tel.: +1 (770) 751 7332 Fax: +1 (770) 751 7334 Email: meetings@imedex.com www.imedex.com

• DiscussinsightsintothebiologyofCLL

• Discussevidenced-basedapproachestotherapy in CLL in both the frontline and relapsed setting

• Reviewexperimentalandrecentlyapproved agents in CLL

• Reviewthemostuptodateclinicaltrialdata in lymphoplasmocytic disorders

• DiscussthenewWHOclassification of lymphoma

• Commentontheevolutionandfutureoftreatment for Hodgkin’s disease

• Reviewtheoptimalfrontlinestrategyforpatients with peripheral T cell lymphoma

• Discussprogressmadeincutaneous T cell lymphoma

• Debatetheaggressivetreatmentofmantlecell lymphoma

• Improvepreventionandtreatmentofcentral nervous system lymphoma

• Commentontheroleofepigenetictargeting of large cell lymphoma

• Utilizeprognosticfactorstooptimizetreatment of low grade lymphoma

• Reviewtreatmentoflymphomasoftheeye

• Discussutilityandsafetyofnovelagentsinlow grade lymphoma

• DebatetheroleofPETscansinHodgkin’sand NHL

• Reviewupdatesinmyelomabiology,includingcelltrafficking,mobilizationandtargeting the cell cycle

• Reviewtheevaluationofminimalresidualdisease in myeloma as well as the IMW consensus on response criteria

• Discussthecurrentstateoftheartintargeted therapy for myeloma

• Reviewevidence-basedtreatmentoptionsfor poor risk and non-transplant eligible patients in the frontline

• Discussevidence-basedtreatmentoptionsfor consolidation in patients with good prognostic indicators

• Reviewnovelcombination therapies for the treatment of relapsed/refractory myeloma

• Reviewhighlightsfromthe2009International Myeloma Workshop

C o n t i n u i n g M e d i c a l E d u ca t i o nCME Statement

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to

provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 18.5 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

W h o S h o u l d A tte n dThis educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, radiation oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.

O b j e c t i v e sAfter attending this Congress, participants should be able to:

James R. Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, California

Steven Bernstein, MD University of Rochester Medical Center Rochester, New York

Joan Bladé, MD University of Barcelona Hospital Clinic Barcelona, Spain

Arthur R. Bradwell, MD University of Birmingham Birmingham, United Kingdom

John C. Byrd, MD Ohio State University Columbus, Ohio

Asher Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, New York

Selina Chen-Kiang, PhD Weill Medical College of Cornell University New York, New York

Bruce D. Cheson, MD Georgetown University Hospital Washington, District of Columbia

Bertrand Coiffier, MD Hospices Civils de Lyon Lyon, France

Morton, Coleman, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Raymond L. Comenzo, MD Tufts University Medical Center Boston, Massachusetts

Claire Dearden, BSc, M.D., FRCP, FPCPathRoyal Marsden Hospital Sutton, United Kingdom

Volker Diehl, MD University Hospital of Cologne Cologne, Germany

Angela Dispenzieri, MD Mayo Clinic College of Medicine Rochester, Minnesota

Rebecca Elstrom, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Scott Ely, MD, MPH Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Rafael Fonseca, MD Mayo Clinic Scottsdale,Arizona

Richard R. Furman, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Randy D. Gascoyne, MD British Columbia Cancer Agency Vancouver, British Columbia, Canada

Philip R. Greipp, MD Mayo Clinic Rochester, Minnesota

Thomas Habermann, MD Mayo Clinic Rochester, Minnesota

Jean-Luc Harousseau, MD Hoteldieu Hospital Nantes, France

Sandra J. Horning, MD Stanford University Medical Center Stanford, California

Steven Horwitz, MD Memorial Sloan-Kettering Cancer Center New York, New York

Carol Ann Huff, MDJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland

Martin Hutchings, MD Copenhagen University Hospital Copenhagen, Denmark

Sundar Jagannath, MD St. Vincent’s Comprehensive Cancer Center New York, New York

Brad Kahl, MD University of Wisconsin Carbone Comprehensive Cancer Center Madison, Wisconsin

Neil Kaye, MD Mayo Clinic Rochester, Minnesota

Eva Kimby, MD, PhD Karolinska Institute at Huddinge University Hospital Stockholm, Sweden

Suzanne Lentzsch, MD, PhD University of Pittsburgh Medical Center Pittsburgh, Pennsylvania

John P. Leonard, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Sagar Lonial, MD Emory University Atlanta, Georgia

Tomer Mark, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Peter Martin, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Peter McLaughlin, MD University of Texas M. D. Anderson Cancer Center Houston, Texas

Fa c u lt y

October 22-24, 2009 I New York, New York I The Waldorf=Astoria

C o rp o ra te S u p p o rtThe following companies have provided an educational grant in support of this Congress:

Ari Melnick, MD Albert Einstein College of Medicine Bronx, New York

Ruben Niesvizky, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Antonio Palumbo, MD University of Torino Torino, Italy

Roger Pearse, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York

Kanti Rai, MD Long Island Jewish Medical Center Albert Einstein College of Medicine New Hyde Park, New York

S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota

Steven Rosen, MD Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois

Stephen Schuster, MD University of Pennsylvania Philadelphia, Pennsylvania

Keith Stewart, M.B.Ch.B Mayo Clinic Scottsdale,Arizona

Wayne Tam, MD, PhD Weill Cornell Medical Center New York, New York

David J. Wolf, MD Weill Cornell Medical College New York, New York

Platinum

Genentech BioOncology and Biogen Idec

Millennium Pharmaceuticals, Inc.

Silver

Corporate

Awards Support

E x h i b i t o rThe following companies are exhibitors at this Congress:

Lippincott Williams

& Wilkins

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1 (770) 751 7332 or by email at cme@imedex.com.

8:00 am Welcome Morton Coleman, MD

CLL Section

8:05 am Introduction Richard R. Furman, MD Session I: Biology of CLL Moderator: John C. Byrd, MD

8:10 am New insights into CLL biology Speaker invited

8:30 am CLL genomics and epigenetics: What’sonthehorizonforclinicians? John C. Byrd, MD

8:50 am How do we make sense of prognostic markers in CLL when treatingpatients? Kanti Rai, MD

9:10 am Panel discussion questions

9:30 am Break Session II: Treatment of CLL Moderator: Richard Furman, MD

9:50 am Evidence-based approaches for treatment-naïve patients Neil Kaye, MD

10:10 am Evidence-based approaches for treating relapsed/ refractory patients Claire Dearden, BSc, MD, FRCP, FPCPath

10:30 am Latest results with IMiDS compounds in CLL: How do we managetherashandflare? Asher Chanan-Khan, MD

10:50 am Experimental and recently approved novel agents in CLL Richard R. Furman, MD

11:10 am Panel discussion

11:20 am Presentation of the best CLL abstract

11:30 am Luncheon Symposium

Session III: Lymphoplasmocytic disorders Moderator: David J. Wolf, MD

1:30 pm Waldenstrom’s macroglobulinemia: An update Eva Kimby, MD, PhD

1:50 pm POEMS and Castleman’s disease: Is therearolefornovelagents? Angela Dispenzieri, MD

2:10 pm Amyloidosis: Recent data Raymond L. Comenzo, MD

2:30 pm Break

Lyphoma Section

2:50 pm Introduction John P. Leonard, MD Session IV: Biology of lymphoma Moderator: Wayne Tam, MD, PhD

2:55 pm The biologic and pathologic basis for the new WHO classification Randy D. Gascoyne, MD

3:15 pm A clinician’s view of the new WHO classification Speaker invited

3:35 pm Panel discussion

3:45 pm Presentation of the best Lymphoma abstract

3:55 pm The SASS Foundation for Medical Research Award Ceremony

Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: John Ultmann Award for Contributions to Lymphoma Research

Recipient: Volker Diehl, MD

Presenter: Speaker invited

4:05 pm Hodgkin’s disease: The past, the present and the future Volker Diehl, MD

4:35 pm Questions and answers

4:45 pm Adjourn

S c i e n t i f i c A g e n daThursday, October 22, 2009

Friday, October 23, 2009

8:00 am Welcome Morton Coleman, MD

8:05 am Introduction John P. Leonard, MD Session V: T cell lymphoma Moderator: Rebecca Elstrom, MD

8:10 am What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agentsandtransplantation? Steven Horwitz, MD

8:30 am Have we made progress in the systemic therapy of treating cutaneousT-celllymphoma? Steven Rosen, MD

8:50 am Angioimmunoblastic lymphadenopathy: What is latestinbiologyandtreatment? Rebecca Elstrom, MD

9:10 am Panel discussion and questions

9:20 am Break Session VI: Mantle cell lymphoma Moderator: John P. Leonard, MD

9:40 am Debate: Should mantle cell lymphoma be treated aggressively fromtheonset?

Pro: Brad Kahl, MD Con: Peter Martin, MD

Moderator: John P. Leonard, MD

10:20 am Discussion and questions Session VII: Special concerns in large cell lymphomaModerator: Thomas Habermann, MD

10:30 am What is the best treat for low stageaggressivelymphomas? Thomas Habermann, MD

10:50 am How to prevent and treatment central nervous system disease Steven Bernstein, MD

11:10 am How can we improve on large cell lymphomatreatment? Bertrand Coiffier, MD

11:30 am Genomic/epigenetic targeting of large cell lymphoma: Does it haveclinicalapplication? Ari Melnick, MD

11:50 am Discussion and questions

12:00 pm Luncheon Symposium Session VIII: Low grade lymphoma Moderator: Peter McLaughlin, MD

2:00pm Isfollicularlymphomacurable? If not, has it become a chronicillness? Peter McLaughlin, MD

2:20 pm Strategies for low grade lymphoma: How to use prognostic indicators in treatment John P. Leonard, MD

2:40 pm Lymphomas of the eye: MALT, follicular, large cell Morton Coleman, MD

3:00 pm Novel agents in low grade lymphoma: More than we canhandle? Bruce D. Cheson, MD

3:20 pm Vaccines redux: Useless oraphoenix? Stephen Schuster, MD

3:40 pm Break Session IX: Hodgkin’s disease: PET scanning Moderator: Morton Coleman, MD

4:00 pm Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma

The new promise of PET scans Martin Hutchings, MD

The new peril of PET scans Sandra J. Horning, MD

Moderator: Morton Coleman, MD

4:30 pm Discussion and questions

4:45 pm Adjourn

Saturday, October 24, 2009

S c i e n t i f i c A g e n da continued

Myeloma Section

8:05 am Introduction Ruben Niesvizky, MD Session X: Biology of myeloma Moderator: Scott Ely, MD, MPH

8:10 am Chromosomes, genomics and proteomics as a disease primer: IsM-SMARTsmart? Rafael Fonseca, MD

8:30 am Myeloma cell trafficking andmobilization Speaker invited

8:50 am Debate: Does the myeloma stem cellexist?Canwetargetitfor therapeuticpurposes? Suzanne Lentzsch, MD, PhD Carol Ann Huff, MD

9:20 am Targeting the cell cycle in myeloma and lymphoma Selina Chen- Kiang, PhD

9:40 am Discussion and questions Session XI: Clinical pathology and myeloma Moderator: Tomer Mark, MD

9:50 am Measurement of free light and heavychains:Applications? Arthur R. Bradwell, MD

10:05 am Minimal residual disease in myeloma: Flow cytometry and molecular techniques: IsMRDclinicallyrelevant? Speaker invited

10:25 am The Tower of Babel: Multiple response criteria and the need for a unified standard. Summary of the IMW consensus on response criteria and relevant outcomes S. Vincent Rajkumar, MD

10:45 am Break

11:05 am The SASS Foundation for Medical Research Award Ceremony

Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: Joseph Michaeli Award for Contributions to Myeloma Research

Recipient: Philip R. Greipp, MD

11:15 am Sass Foundation/ Michaeli Award Lecture

Kinetics, proliferation, and novel agents in myeloma: Is autologous transplantation ananachronism? Philip R. Greipp, MD

11:45 am Presentation of the best Myeloma abstract

11:55 am Special lecture: Targeted therapy in myeloma Keith Stewart, M.B.Ch.B

12:20 pm Questions

12:25 pm Luncheon Symposium Session XII: Clinical cases and debates in myelomaModerator: Ruben Niesvizky, MD

2:15 pm FIRST LINE THERAPY: Clinical case of poor risk patient

Debate: Sequential therapy vs. combination therapy, triplets or more Jean-Luc Harousseau, MD (sequential)

Sagar Lonial, MD (combination)

2:45 pm CONSOLIDATION: Clinical case of good risk patient

Debate: Transplant vs. no transplant

Speaker invited (transplant)

Joan Bladé, MD (no transplant)

3:15 pm FIRST LINE THERAPY: Clinical case of non-transplant candidate

Debate:bortezomibbasedvs. IMiD based

Ruben Niesvizky, MD (bortezomib-based)

Antonio Palumbo, MD (IMiD-based)

H o te l A c co mm o da t i o n sThe Waldorf=Astoria 301 Park Avenue New York, New York 10022 Tel.: +1 (212) 355 3000 Fax: +1 (212) 872 7272 Reservation: (877) 476 8792 www.waldorf.com As one of the first “grand hotels” to combine luxurious elegance with a myriad of amenities and services, the Waldorf=Astoria has been world renowned for over a century. With a reputation for unparalleled hospitality and service, the Art Deco landmark beckons New Yorkers and visitors alike. Since1893,TheWaldorf=Astoriahasepitomizedthequintessential luxury hotel experience. Each spacious, individually decorated guest room and suite offers a rewarding union of timeless elegance and up-to-the-moment convenience, luxurious comfort and classic sophistication. The legendary shops of Fifth and Madison Avenues are only minutes away, as are numerous art galleries and specialty shops. The hotel itself is home to some of the world’s most luxurious boutiques.

For the convenience of attendees, a limited number of rooms have been reserved until September 24, 2009 at a discounted rate of $319.00 single/double occupancy, plus tax, currently at 14.25% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the conference dates or after September 24, 2009.

To reserve your room please contact the Waldorf=Astoria reservations department at (877) 476 8792 or visit the hotel’s website at www.waldorf.com. To receive the group rate, callers must identify themselves as being with the Lymphoma & Myeloma 2009 group. Internet users must enter the Group/Convention Code: LYM. Reservation requests received after September 24, 2009 may not be guaranteed the group rate.

Session XIII: Relapse/ refractory disease Moderator: Roger Pearse, MD

3:45 pm SECOND LINE THERAPY: Novel combination therapies for the treatment of relapsed/ refractory multiple myeloma: Current phase I/II combinations using IMiD compounds and proteasome inhibitors as the backbone James R. Berenson, MD

4:05 pm Questions Session XIV: Special lecture Moderator: Morton Coleman, MD, FACP

4:10 pm Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure inmyeloma? Sundar Jagganath, MD

4:40 pm Questions

4:50 pm Adjourn

* Please visit www.imedex.com for the most up-to-date agenda and to register.

Q u o t e s f r o m Y o u r c o l l e a g u e s :

“Lymphoma & Myeloma is the best international Congress on these subjects.”

“Outstanding level of research topics.”

“This Congress is truly comprehensive.”

“Excellent program, very informative.”

“Thank you for a great Congress – wonderful speakers!”

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the

event of cancellation. The event agenda content is subject to change without notice.

r Check if you require special facilities or assistance and attach a note with specific details and requirements.

__________________________________________________________________________________ FIRST NAME LAST NAME

DEGREE: r MD r PhD r PharmD r RN r Other Degree ____________________________________

SPECIALTY: r Hematology r Medical Oncology r Nursing r Pathology r Radiation Oncology r Surgery rOther _______________________________________________________________________ ________________________________________________________________________________________ EMAIL ADDRESS ________________________________________________________________________________________ TELEPHONE FAX ________________________________________________________________________________________ INSTITUTE DEPARTMENT ________________________________________________________________________________________ ADDRESS

________________________________________________________________________________________ CITY STATE / PROVINCE

________________________________________________________________________________________ ZIP / POSTAL CODE COUNTRY

C O N F E R E N C E R E G I S T R AT I O N

R E G I S T R AT I O N F E E S

Regular r $495 Physiciansr $345 Pharmacists* (If payment received by October 15, 2009)Full/Onsite r $595 Physiciansr $395 Pharmacists* (To register after October 15, 2009)

r $99 Nurses/Residents/Students* (*proof of eligibility must accompany registration)

Credit card transactions will appear under the name Imedex Inc. on your next statement.

To pre-register, registration and payment must be received no later than Thursday, October 15, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure that the meeting is being held as scheduled and to confirm that the meeting is not full.

For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than Thursday, October 15, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after Thursday, October 15, 2009.

r American Express r MasterCard r Visa r Check in the amount of $______________________________

Card No. ____________________________________________ Exp. Date: _______________ /________________

Cardholder’s Name: ___________________________________ Signature: _______________________________

PAY M E N T M E T H O D

Four EASY ways to register:October 22-24, 2009 I New York, New York I The Waldorf=Astoria

A115.01

R e g i s tra t i o n To Register:You may register onlineby Thursday, October 15, 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than Thursday, October 15, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received. Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than Thursday, October 15, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 15, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Registration and Information Desk will be staffed:

Thursday, October 22, 2009: 7:00 am – 4:30 pm

Friday, October 23, 2009: 7:30 am – 4:30 pm

Saturday, October 24, 2009: 7:30 am – 4:30 pm

R e g i s tra t i o n Fe e sRegular (Physicians) $495 ...............................................................(Pharmacists)* $345If payment received by October 15, 2009

Full/Onsite (Physicians) $595 .........................................................(Pharmacists)* $395To register after October 15, 2009

Nurses/Residents/Students* .......................................................$99*proof of eligibility must accompany registration

ONLINE. . .www.imedex.com

FAX US. . .+1 (678) 242 0920

C ALL US. . . +1 (678) 242 0906

MAIL US. . . Imedex, 4325 Alexander Dr. Alpharetta, GA, 30022-3740, USA

3 WAYS TO LEARN:

Visit www.imedex.com to learn more

LIVE meetings are produced by Imedex in 15 countries

PRINT materials are produced by Imedex for your reference needs

ONLINE products are produced by Imedex in 6 user-friendly formats

4 WAYS TO REGISTER:

4325

Ale

xan

der

Dri

veA

lph

aret

ta, G

eorg

ia 3

0022

-374

0, U

SA

Impo

rtant

Dates

Ab

stra

ct N

oti

fica

tio

ns

Mai

led

Sep

tem

ber

25,

200

9

Ab

stra

ct P

rese

nte

r R

egis

trat

ion

Dea

dlin

e O

cto

ber

8, 2

009

Reg

ula

r R

egis

trat

ion

Dea

dlin

e

Oct

ob

er 1

5, 2

009

Pre

sen

tati

on

Dat

es

Oct

ob

er 2

2-24

, 200

9

Oct

ob

er 2

2-2

4, 2

00

9 I

New

Yo

rk, N

ew Y

ork

I Th

e W

ald

orf

=A

sto

ria

Dar

k B

lue

C10

0, M

55, Y

0, K

55

Lig

ht

Blu

e C

29, M

12, Y

0, K

0

Ora

ng

e C

0, M

66, Y

100,

K0

10%

Imed

ex®

is c

om

mit

ted

to e

nvir

on

men

tal e

xcel

len

ce.

This

pu

blic

atio

n is

pri

nte

d o

n F

SC-c

erti

fied

pap

er, w

hic

h is

ac

id-f

ree,

an

d c

on

tain

s 10

% p

ost

-co

nsu

mer

recy

cled

co

nte

nt.

Imed

ex is

a b

ran

d a

nd

ass

um

ed

nam

e u

sed

by

Imed

ex, L

LC (h

ereb

y re

ferr

ed to

as

Imed

ex).

Imed

ex is

so

lely

resp

on

sib

le fo

r th

is a

gen

da’

s co

nte

nt.

Alt

ho

ug

h Im

edex

att

emp

ts

to e

nsu

re t

hat

th

e in

form

atio

n in

o

ur p

rog

ram

is a

ccu

rate

an

d t

imel

y,

mat

ters

an

d o

pin

ion

s d

iscu

ssed

an

d/

or p

rese

nte

d w

ith

resp

ect

to c

linic

al

mat

ters

are

th

ose

of t

he

dis

cuss

ion

p

arti

cip

ants

on

ly, a

nd

no

t n

eces

sari

ly

tho

se o

f Im

edex

. Mo

reov

er, a

lth

ou

gh

Im

edex

att

emp

ts to

iden

tify

an

d

inte

gra

te t

he

mo

st q

ual

ified

med

ical

p

rofe

ssio

nal

s in

ou

r pro

gra

m, T

O

THE

FULL

EST

EXTE

NT

PERM

ITTE

D

BY

LA

W, I

MED

EX E

XPR

ESSL

Y

DIS

CLA

IM A

LL W

ARR

AN

TIES

, EIT

HER

EX

PRES

S O

R IM

PLIE

D, S

TATU

TORY

O

R O

THER

WIS

E, IN

CLU

DIN

G B

UT

NO

T LI

MIT

ED T

O T

HE

IMPL

IED

W

ARR

AN

TIES

OF

MER

CH

AN

TAB

ILIT

Y,

NO

N-I

NFR

ING

EMEN

T O

F TH

IRD

PA

RTI

ES’ R

IGH

TS, A

ND

FIT

NES

S FO

R A

PA

RTI

CU

LAR

PURP

OSE

, WIT

H R

ESPE

CT

TO T

HE

CO

NTE

NT

PRES

ENTE

D.

IMED

EX F

UR

THER

MA

KES

NO

RE

PRES

ENTA

TIO

NS

OR

WA

RRA

NTI

ES

AB

OU

T TH

E A

CC

UR

AC

Y, R

ELIA

BIL

ITY,

C

OM

PLET

ENES

S O

R TI

MEL

INES

S

OF

THE

CO

NTE

NT

OR

AN

Y

MAT

ERIA

L PR

ESEN

TED

.

In a

dd

itio

n, t

he

mat

eria

l pre

sen

ted

an

d re

late

d d

iscu

ssio

ns

are

no

t in

ten

ded

to b

e m

edic

al a

dvi

ce, a

nd

th

e p

rese

nta

tio

n o

r dis

cuss

ion

of s

uch

m

ater

ial i

s n

ot

inte

nd

ed to

cre

ate

and

d

oes

no

t es

tab

lish

a p

hys

icia

n-p

atie

nt

rela

tio

nsh

ip. M

edic

al a

dvi

ce o

f an

y n

atu

re s

ho

uld

be

sou

gh

t fr

om

an

in

div

idu

al’s

ow

n p

hys

icia

n.

Nei

ther

Imed

ex n

or a

ny

of i

ts

sub

sid

iari

es o

r affi

liate

s is

affi

liate

d

wit

h o

r fo

rmal

ly e

nd

ors

ed b

y a

m

edic

al s

oci

ety.

Co

pyr

igh

t 20

09 Im

edex

®, L

LC.

All

rig

hts

rese

rved

.